Silence Therapeutics plc Stock OTC Markets
Stocks
SLNCF
GB00B9GTXM62
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.200 USD | -0.45% |
|
-.--% | +10.00% |
| 06-25 | European Equities Traded in US as ADRs Rise in Thursday Trading | MT |
| 06-24 | European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading | MT |
| Market Cap | 373M 496M 435M 401M 704M 47.15B 719M 4.82B 1.87B 23.14B 1.86B 1.82B 80.55B | P/E 2026 * |
-17.6x | P/E 2027 * | -15.6x |
|---|---|---|---|---|---|
| Enterprise Value | 227M 301M 265M 244M 428M 28.66B 437M 2.93B 1.14B 14.07B 1.13B 1.11B 48.97B | EV / Sales 2026 * |
91x | EV / Sales 2027 * | 36.1x |
| Free-Float |
69.36% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Silence Therapeutics plc
| 1 day | -0.45% | ||
| 1 month | +107.55% | ||
| 3 months | +10.00% | ||
| 6 months | +10.00% | ||
| Current year | +10.00% |
| 1 month | 1.8 |  | 2.21 |
| Current year | 1.06 | | 2.63 |
| 1 year | 1.06 | | 2.63 |
| 3 years | 0.5 | | 14.75 |
| 5 years | 0.5 | | 46.5 |
| 10 years | 0.5 | | 46.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Iain Ross
CEO | Chief Executive Officer | 72 | 2025-12-13 |
Rhonda Hellums
DFI | Director of Finance/CFO | 54 | 2022-02-20 |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 2020-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
David Lemus
BRD | Director/Board Member | 63 | 2018-06-20 |
Iain Ross
CHM | Chairman | 72 | 2019-11-30 |
Rhonda Hellums
BRD | Director/Board Member | 54 | 2025-12-17 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.45% | -.--% | - | - | 496M | |
| +0.04% | +4.62% | +0.57% | +6.16% | 48.62B | |
| +0.12% | +10.45% | +408.29% | +600.97% | 39.86B | |
| +5.17% | +9.47% | +24.96% | -9.60% | 33.91B | |
| +2.02% | +4.91% | +18.59% | +63.06% | 32.32B | |
| +0.69% | +1.04% | +14.23% | +30.86% | 24.73B | |
| +0.40% | +12.51% | - | - | 16.63B | |
| +2.64% | +6.00% | +69.30% | +126.33% | 15.52B | |
| +0.06% | +0.32% | +12.92% | +17.62% | 13.63B | |
| +0.77% | +10.67% | +17.58% | -30.04% | 13.41B | |
| Average | +1.15% | +7.05% | +70.81% | +100.67% | 26.52B | |
| Weighted average by Cap. | +1.35% | +7.14% | +88.24% | +128.51% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.5M 3.31M 2.91M 2.68M 4.71M 315M 4.8M 32.21M 12.48M 155M 12.44M 12.17M 538M | 3.44M 4.57M 4.01M 3.69M 6.49M 434M 6.62M 44.41M 17.21M 213M 17.16M 16.78M 742M |
| Net income | -50.34M -66.85M -58.69M -54.02M -94.94M -6.36B -96.87M -650M -252M -3.12B -251M -246M -10.86B | -84.67M -112M -98.71M -90.86M -160M -10.69B -163M -1.09B -423M -5.25B -422M -413M -18.26B |
| Net Debt | -146M -194M -171M -157M -276M -18.49B -282M -1.89B -732M -9.07B -730M -714M -31.58B | -249M -331M -291M -268M -470M -31.49B -480M -3.22B -1.25B -15.46B -1.24B -1.22B -53.79B |
| Date | Price | Change | Volume |
|---|
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SLN Stock
- SLNCF Stock
Select your edition
All financial news and data tailored to specific country editions
